In summary, we developed and validated a new predictive biomarker named NPI+IHC4 in predicting pCR following NAC in ER+ breast cancer patients and demonstrated that NPI+IHC4 outperformed NPI or IHC4 score alone and other clinicopathological factors in predicting pCR. The gene discussed is ESR1; the disease is breast cancer.